Sumatran Relief contains: The active substance is sumatriptan. Each tablet contains 50mg sumatriptan (as sumatriptan succinate).
Other ingredients are: Ammonium methacrylate copolymer type A, carmellose sodium (E466), microcrystalline cellulose(E450), croscarmellose sodium (E468), lactose monohydrate, magnesium sterate (E470b), flavouring (grape), red iron oxide (E172), yellow iron oxide (E172)
Who can use Sumatran Relief Migraine Tablets?
This medicine can be used adults 18 to 65 years
How to use?
The recommended dose is 50mg sumatriptan once migraine has started. If migraine improves after first dose (50mg) but symptons reappear an additional 50mg can be taken. You must wait at least 2 hours after taking the first dose before you can take the second dose. Do not take more than 100mg in 24hr period.
If the first tablet has no effect, you can take other painkillers such as paracetamol.
Swallow this tablets with a glass of water.
If you are pregnant or breast-feeding.
If you are pregnant or trying to become pregnant, do not take Sumatran Relief. Do not take this medication if you are breastfeeding.
Driving and using machines.
Wait until you have found out how you react to this medication before you drive or operate machinery.
Common side effects.
Feeling dizzy, feeling sleepy, unusual sensation or tingling, hot flushes, breathlessness, aching muscles and temporary increase of blood pressure soon after intake.
Contraindications - Do Not Take Sumatran Relief If Any Of The Following Apply To You
- Hypersensitivity to the active substance or to any of the excipients
- Hypersensitivity to sulphonamides
- Sumatriptan should not be used prophylactically
- A history of myocardial infarction, ischaemic heart disease or coronary vasospasm (Prinzmetal’s angina)
- Peripheral vascular disease
- Symptoms or signs consistent with ischaemic heart disease
- A history of stroke (cerebrovascular accident (CVA)) or transient ischaemic attack (TIA)
- A history of cardiac arrhythmia
- Renal or hepatic impairment
- Hypertension or a history of hypertension
- History of seizures or other risk factors which lower the threshold
- Concomitant administration of preparations containing ergotamine or ergotamine derivatives (including methysergide) or any triptan/5 hydroxytryptamine 1 (5-HT1) receptor agonist (see section 4.5)
- Concomitant use of monoamine oxidase inhibitors and the use of sumatriptan within 2 weeks after discontinuation of therapy with monoamine oxidase inhibitors
- Management of basilar, hemiplegic or ophthalmoplegic migraine.
Special warnings and precautions for use
- Sumatriptan should only be used where a clear diagnosis of "migraine" has been made by a doctor initally. For pharmacy supply, patients should have an established pattern of migraine (a history of five or more migraine attacks occurring over a period of at least 1 year)
- Migraineurs whose typical headaches persist for longer than 24 hours should seek advice from their doctor
- Migraneurs who experience four or more migraine attacks per month should be referred to a doctor for ongoing management
- Migraneurs in whom the pattern of symptoms has changed or whose attacks have become more frequent, more persistant, or more severe, or who do not recover completely between attacks, should seek advice from their doctor
- Following administration, sumatriptan can be associated with transient symptoms including chest pain and tightness, which may be intense and involve the throat (see section 4.8). Where such symptoms are thought to indicate ischaemic heart disease, no further doses of sumatriptan should be given. A medical evaluation should be obtained immediately
- It should be noted that migraineurs may be at increased risk of certain cerebrovascular events (e.g. CVA, TIA). Medication should be stopped if they experience atypical symptoms (i.e. unilateral motor weakness, double vision, ataxia etc.) and they should seek medical advice
- Sumatriptan should not been used in migraineurs without a prior cardiac risk assessment by a doctor or pharmacist. As migraine is a chronic condition, cardiovascular risk should be evaluated regularly in patients who use sumatriptan intermittently, over the longer term, to manage their migraine
- Women with migraine who are taking the combined oral contraceptive have an increased risk of stroke and should seek advice from their doctor if migraine attacks started recently (within the last 3 months), migraine symptoms have worsened, or they have migraine with aura
- Sumatriptan should not be given to patients with risk factors for ischaemic heart disease, including those patients who are heavy smokers or users of nicotine substitution therapies, without prior cardiovascular evaluation (see section 4.3)
- Special consideration should be given to postmenopausal women and males over 40 years of age with these risk factors. Risk factors for heart disease include hypercholesterolaemia, regular smoking, marked obesity, diabetes or a family history of early heart disease (father/brother developed heart disease before the age of 55, mother/sister developed heart disease before the age of 65). These evaluations however, may not identify every patient who has cardiac disease and, in very rare cases, serious cardiac events have occurred in patients without underlying cardiovascular disease.
KEEP ALL MEDICINES OUT OF THE EACH OF CHILDREN.
READ THE PATIENT LEAFLET BEFORE TAKING THIS MEDICATION.